Literature DB >> 33649526

Delayed retroperitoneal liposarcoma diagnosis and management in a patient with massive obesity.

Claire Rives-Lange1,2,3, Tigran Poghosyan4,5, Charles Dariane4,6, Richard Douard4,5, Elise Mongeois7, Amel Ait Boudaoud8,4, Charles Barsamian8, Alina Radu8, Christine Lagorce9, Virginie Verkarre9, Frédérique Larousserie4,10, Jean-François Perregaux8, Fransisca Joly11, Claire Carette8,4, Sébastien Czernichow8,4,12.   

Abstract

People suffering from extreme obesity may be exposed to delayed diagnosis and treatment of cancer. A 37-year-old woman (weight = 245 kg, body mass index (BMI) = 79 kg/m2), presented a sepsis associated with nonspecific abdominal pain for 4 months. After several unsuccessful attempts due to her weight and a large waist circumference, abdominal CT scan was finally successfully performed and showed a large retroperitoneal mass. An ultrasound-guided core needle biopsy was performed and was in favor of a liposarcoma. Surgery was performed to remove the entire tumor of an estimated weight of 98 kg, a giant retroperitoneal dedifferentiated liposarcoma. This case highlights the difficulties to screen, diagnose, and manage cancers encountered in patients suffering from massive obesity.

Entities:  

Year:  2021        PMID: 33649526     DOI: 10.1038/s41430-020-00855-5

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  2 in total

Review 1.  Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas.

Authors:  John C Bradley; Richard Caplan
Journal:  Am Surg       Date:  2002-01       Impact factor: 0.688

2.  [Retroperitoneal liposarcoma].

Authors:  Mohamed Said Basly; Hassen Khouni; Mohamed Dridi; Wady Hellara; Houssem EI Arbi; Rochdi Kid; Mohamed Mokhtar Oueld Sidi; Samir Ghozzi; Naoufel Ben Raies
Journal:  Tunis Med       Date:  2009-08
  2 in total
  1 in total

Review 1.  Retroperitoneal Sarcoma Care in 2021.

Authors:  Erika Schmitz; Carolyn Nessim
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.